Dr. Jiaoti Huang’s laboratory has been studying the molecular mechanisms by which prostate cancer becomes insensitive to hormonal therapy and progresses to castration resistant tumors. His lab is actively engaged in drug discovery and in developing tumor models that can be used for the development of tools used in diagnosis, imaging, prevention and therapy of prostate cancer.
Selected Cancer-Related Publications:
Huang J, Witte ON. A seminal finding for prostate cancer? N Engl J Med. 2010 Jan 14;362(2):175-6.
Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2610-5. Epub 2010 Jan 25.
Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang LS, Yang Q, Huang J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate. 2009 May 15;69(7):787-98.
Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol. 2009 Feb;40(2):252-8. Epub 2008 Oct 5.
Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem. 2007 Feb 9;282(6):3571-83. Epub 2006 Dec 4.